Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 5/20 | 0.46 |
| ▸ | HRH1 | P35367 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL173872 | 0.77 | HRH1 (0.46) | AOC3HRH1HTR2ATAAR1SLC6A4 | |
| SCHEMBL8085621 | 0.75 | HRH1 (0.50) | AOC3HRH1HTR2ATAAR1SLC6A4 | |
| SCHEMBL8085619 | 0.75 | HRH1 (0.50) | AOC3HRH1HTR2ATAAR1SLC6A4 | |
| SCHEMBL7606834 | 0.72 | GABBR2 (0.51) | HRH1HTR2ATAAR1CYP1A2CYP3A4 | |
| SCHEMBL27949747 | 0.72 | SRC (0.46) | HRH1 | |
| SCHEMBL6727027 | 0.72 | TDP1 (0.48) | SLC6A4SLC6A2SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL11658798 | 0.70 | AOC3 (0.49) | AOC3TAAR1LMNA | |
| SCHEMBL31480056 | 0.69 | LMNA (0.46) | AOC3CYP2D6TSHRLMNA | |
| SCHEMBL6522565 | 0.67 | LMNA (0.44) | AOC3CYP2D6TSHRLMNA | |
| SCHEMBL42066 | 0.67 | HRH1 (0.62) | AOC3HRH1HTR2ATAAR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021211-A1 | Dual mode radiotracer and -therapeutics | UNIV MUENCHEN TECH (DE) | 2026-01-22 | — | — | US | claimed |
| EP-4651910-A1 | DUAL LABELLED COMPOUNDS TARGETING THE PROSTATE SPECIFIC MEMBRANE ANTIGEN | Centre Hospitalier Universitaire Vaudois (CHUV) (CH) | 2025-11-26 | — | — | EP | claimed |
| US-12419976-B2 | Hybrid tracers for targeted cancer imaging and treatment | ACADEMISCH ZIEKENHUIS LEIDEN (H.O.D.N. LUMC) GMBH (NL) | 2025-09-23 | — | — | US | claimed |
| US-20250288704-A1 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | Technische Universität München (DE) | 2025-09-18 | — | — | US | claimed |
| US-12390540-B2 | Dual mode radiotracer and -therapeutics | Technische Universität München (DE) | 2025-08-19 | — | — | US | claimed |
| US-20250213736-A1 | SCISSION-ENHANCED NUCLEAR IMAGING AND TREATMENT | THE GENERAL HOSPITAL CORPORATION | 2025-07-03 | — | — | US | claimed |
| WO-2025072955-A1 | NOVEL COMPOSITIONS, METHODS OF MANUFACTURE AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-04-03 | — | — | WO | claimed |
| EP-3478162-B1 | GRANZYME B DIRECTED IMAGING AND THERAPY | MASSACHUSETTS GEN HOSPITAL (US) | 2025-03-19 | — | — | EP | claimed |
| EP-4291250-B1 | DUAL MODE RADIOTRACER AND THERAPEUTICS | UNIV MUENCHEN TECH (DE) | 2025-01-15 | — | — | EP | claimed |
| US-20240399001-A1 | RADIOTRACERS AND THERAPEUTICS BINDING TO FIBROBLAST ACTIVATION PROTEIN (FAP) | Blue Earth Diagnostics Limited (GB) | 2024-12-05 | — | — | US | claimed |
| WO-2023283627-A1 | RADIOTRACERS AND THERAPEUTICS BINDING TO FIBROBLAST ACTIVATION PROTEIN (FAP) | Blue Earth Diagnostics Limited (GB) | 2023-01-12 | — | — | WO | claimed |
| US-20220370649-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | UNIV MUENCHEN TECH (DE) | 2022-11-24 | — | — | US | claimed |
| WO-2022238553-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-11-17 | — | — | WO | claimed |
| WO-2022171869-A1 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-08-18 | — | — | WO | claimed |
| WO-2022171901-A1 | DUAL MODE RADIOTRACER AND THERAPEUTICS | Technische Universität München (DE) | 2022-08-18 | — | — | WO | claimed |
| EP-4043041-A1 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-08-17 | — | — | EP | claimed |
| US-20220175975-A1 | HER3 Peptides for Imaging and Radiotherapy | THE GENERAL HOSPITAL CORPORATION | 2022-06-09 | — | — | US | claimed |
| US-20220118120-A1 | CANCER DIAGNOSTIC IMAGING AGENTS | Technische Universität München (DE) | 2022-04-21 | — | — | US | claimed |
| WO-2022018264-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | Technische Universität München (DE) | 2022-01-27 | — | — | WO | claimed |
| WO-2008074960-A2 | NEW CONJUGATES FOR THERAPEUTIC PURPOSES AND/OR AS DIAGNOSIS AND/OR IMAGING AGENTS AND METHOD FOR PREPARING THE SAME | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2008-06-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370649-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | PAICS, SSTR2, SSTR1 | AOC3 3879/4885HRH1 3257/4885HTR2A 1408/4885 |
| US-12419976-B2 | Hybrid tracers for targeted cancer imaging and treatment | HNRNPF, ANXA3, SLC67A1 | AOC3 946/4885HRH1 3564/4885HTR2A 3232/4885 |
| US-20260021211-A1 | Dual mode radiotracer and -therapeutics | FOLH1, SLC19A1, KLK3 | AOC3 3842/4885HRH1 1601/4885HTR2A 2629/4885 |
| US-20240399001-A1 | RADIOTRACERS AND THERAPEUTICS BINDING TO FIBROBLAST ACTIVATION PROTEIN (FAP) | FAP, FIBP, FGFR1 | AOC3 4464/4885HRH1 4217/4885HTR2A 4109/4885 |
| US-20250288704-A1 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | CXCR4, CXCR1, CXCR3 | AOC3 3987/4885HRH1 288/4885HTR2A 2491/4885 |
| US-20220175975-A1 | HER3 Peptides for Imaging and Radiotherapy | ERBB3, EGFR, NGLY1 | AOC3 2527/4885HRH1 680/4885HTR2A 2695/4885 |
| US-20250213736-A1 | SCISSION-ENHANCED NUCLEAR IMAGING AND TREATMENT | FCGR3B, CTSE, RAD18 | AOC3 1826/4885HRH1 1762/4885HTR2A 3288/4885 |
| US-12390540-B2 | Dual mode radiotracer and -therapeutics | PAICS, SSTR2, SSTR1 | AOC3 3879/4885HRH1 3257/4885HTR2A 1408/4885 |
| US-20220118120-A1 | CANCER DIAGNOSTIC IMAGING AGENTS | FOLH1, FOLR1, KLK3 | AOC3 3867/4885HRH1 4520/4885HTR2A 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.